Comparing the results from a Swedish pregnancy cohort using data from three automated placental growth factor immunoassay platforms intended for first‐trimester preeclampsia prediction
Acta Obstetricia et Gynecologica Scandinavica · 2023
DOI: 10.1111/aogs.14615 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2023. Verfasst von Ylva Carlsson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Pre-Eclampsia, Pregnancy Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Frimurarfonden Barnhusdirektionen Foundation, Region Skåne Research funds, Regional research funds Uppsala/Örebro region.
Abstract (Originalsprache)
Introduction
Risk evaluation for preeclampsia in early pregnancy allows identification of women at high risk. Prediction models for preeclampsia often include circulating concentrations of placental growth factor (PlGF); however, the models are usually limited to a specific PlGF method of analysis. The aim of this study was to compare three different PlGF methods of analysis in a Swedish cohort to assess their convergent validity and appropriateness for use in preeclampsia risk prediction models in the first trimester of pregnancy. Material and methods First‐trimester blood samples were collected in gestational week 11 +0 to 13 +6 from 150 pregnant women at Uppsala University Hospital during November 2018 until November 2020. These samples were analyzed using the different PlGF methods from Perkin Elmer, Roche Diagnostics, and Thermo Fisher Scientific.
Results
There were strong correlations between the PlGF results obtained with the three methods, but the slopes of the correlations clearly differed from 1.0: PlGF PerkinElmer = 0.553 (95% confidence interval [CI] 0.518–0.588) * PlGF Roche –1.112 (95% CI −2.773 to 0.550); r = 0.966, mean difference −24.6 (95% CI −26.4 to −22.8). PlGF PerkinElmer = 0.673 (95% CI 0.618–0.729) * PlGF ThermoFisher –0.199 (95% CI −2.292 to 1.894); r = 0.945, mean difference −13.8 (95% CI −15.1 to −12.6). PlGF Roche = 1.809 (95% CI 1.694–1.923) * PlGF PerkinElmer +2.010 (95% CI −0.877 to 4.897); r = 0.966, mean difference 24.6 (95% CI 22.8–26.4). PlGF Roche = 1.237 (95% CI 1.113–1.361) * PlGF ThermoFisher +0.840 (95% CI −3.684 to 5.363); r = 0.937, mean difference 10.8 (95% CI 9.4–12.1). PlGF ThermoFisher = 1.485 (95% CI 1.363–1.607) * PlGF PerkinElmer +0.296 (95% CI −2.784 to 3.375); r = 0.945, mean difference 13.8 (95% CI 12.6–15.1). PlGF ThermoFisher = 0.808 (95% CI 0.726–0.891) * PlGF Roche –0.679 (95% CI −4.456 to 3.099); r = 0.937, mean difference −10.8 (95% CI −12.1 to −9.4).
Conclusion
The three PlGF methods have different calibrations. This is most likely due to the lack of an internationally accepted reference material for PlGF. Despite different calibrations, the Deming regression analysis indicated good agreement between the three methods, which suggests that results from one method may be converted to the others and hence used in first‐trimester prediction models for preeclampsia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Center of Perinatal Medicine and Health, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
- Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden.
- Department of Women's Health, Division of Obstetrics, Karolinska University Hospital, Stockholm, Sweden.
- Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
- Department of Women's and Children's Health, Karolinska Institute and Center for Fetal Medicine, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Ylva Carlsson, Anna Sandström
Förderung
- Frimurarfonden Barnhusdirektionen Foundation
- Region Skåne Research funds
- Regional research funds Uppsala/Örebro region
- Stiftelsen Handlanden Hjalmar Svenssons
- Stiftelsen Mary von Sydows, född Wijk, donationsfond: YC
- Stiftelserna Wilhelm och Martina Lundgrens
- Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement
- The Gothenburg Society of Medicine
Zitieren
APA
Carlsson, Y., Sandström, A., Bergman, L., Conner, P., Hansson, S., Kublickas, M., Görmüş, U., Lindgren, P., Oleröd, G., Wikström, A. K., & Larsson, A. (2023). Comparing the results from a Swedish pregnancy cohort using data from three automated placental growth factor immunoassay platforms intended for first‐trimester preeclampsia prediction. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14615
Vancouver
Carlsson Y, Sandström A, Bergman L, Conner P, Hansson S, Kublickas M, et al. Comparing the results from a Swedish pregnancy cohort using data from three automated placental growth factor immunoassay platforms intended for first‐trimester preeclampsia prediction. Acta Obstetricia et Gynecologica Scandinavica. 2023. doi:10.1111/aogs.14615
BibTeX
@article{Carlsson2023,
author = {Carlsson, Ylva and Sandström, Anna and Bergman, Lina and Conner, Peter and Hansson, Stefan and Kublickas, Marius and Görmüş, Uzay and Lindgren, Peter and Oleröd, Göran and Wikström, Anna-Karin and Larsson, Anders},
title = {Comparing the results from a Swedish pregnancy cohort using data from three automated placental growth factor immunoassay platforms intended for first‐trimester preeclampsia prediction},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2023},
doi = {10.1111/aogs.14615}
}
EUVIMED